Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViGeM: Vinorelbine vs Gemcitabine for Stem Cell Mobilization
NCT02791373Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- Mar 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in multiple myeloma (MM) and amyloidosis (2 arms), sponsored by Insel Gruppe. Primary endpoint: CD34+ peripheral blood stem cells at Day 8. Started Mar 2014; status: completed.
02
Drugs
gemcitabine
03
Conditions
multiple myeloma (MM)amyloidosis
Beyond the preview
Go deeper on NCT02791373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791373.